Tag:
Votrient
Latest Headlines
Latest Headlines
FDA stamps approval on GSK cancer drug Votrient
The FDA nod follows a study that showed that patients on Votrient lived three months longer than those on a placebo without their cancer getting worse, the agency said.
FDA panel shoots down Merck/Ariad cancer drug as GSK marches on
Merck and Ariad Pharmaceuticals saw their hopes for approval of their targeted cancer drug ridaforolimus dim after an FDA panel voted not to recommend approval of the therapy for sarcomas.
FDA panel backs GSK's Votrient for soft-tissue sarcoma
Good news came for GlaxoSmithKline ( $GSK ) Tuesday after the FDA's Oncologic Drugs Advisory Committee voted 11 to 2 in favor of approving Votrient to treat patients with advanced soft tissue sarcoma who have received prior chemotherapy. The FDA approved Votrient in 2009 to treat advanced renal cell carcinoma.
GSK pitches Votrient rebate if trial favors Sutent
Drugmakers have held out plenty of different carrots to induce the U.K.'s cost-effectiveness watchdog to accept expensive meds for use on the National Health Service. Companies have offered paybacks
FDA panel backs Glaxo's new kidney cancer drug
An expert panel gathered by the FDA has endorsed GlaxoSmithKline's new kidney cancer therapy, pazopanib. The group voted unanimously that the drug, which Glaxo plans to market as a treatment for
